X-linked Inhibitor of Apoptosis Protein Inhibits Apoptosis in Inflammatory Breast Cancer Cells with Acquired Resistance to an ErbB1/2 Tyrosine Kinase Inhibitor

Overview

Journal Mol Cancer Ther

Date 2010 Apr 22

PMID 20406946

Citations 43

Authors

Katherine M Aird

Rami B Ghanayem

Sharon Peplinski

Herbert K Lyerly

Gayathri R Devi

Affiliations

Soon will be listed here.

Abstract

Inflammatory breast cancer (IBC) is a highly aggressive subtype of breast cancer that is often characterized by ErbB2 overexpression. ErbB2 targeting is clinically relevant using trastuzumab (anti-ErbB2 antibody) and lapatinib (small-molecule ErbB1/2 inhibitor). However, acquired resistance is a common outcome even in IBC patients who show an initial clinical response, which limits the efficacy of these agents. In the present study, using a clonal population of GW583340 (lapatinib analogue, ErbB1/2 inhibitor)-resistant IBC cells, we identified the overexpression of an antiapoptotic protein, X-linked inhibitor of apoptosis protein (XIAP), in acquired resistance to GW583340 in both ErbB2-overexpressing SUM190 and ErbB1-activated SUM149 cell lines derived from primary IBC tumors. A marked decrease in p-ErbB2, p-ErbB1, and downstream signaling was evident in the GW583340-resistant cells (rSUM190 and rSUM149) similar to parental counterparts treated with the drug, suggesting that the primary mechanism of action of GW583340 was not compromised in resistant cells. However, rSUM190 and rSUM149 cells growing in GW583340 had significant XIAP overexpression and resistance to GW583340-mediated apoptosis. Additionally, stable XIAP overexpression using a lentiviral system reversed sensitivity to GW583340 in parental cells. The observed overexpression was identified to be caused by IRES-mediated XIAP translation. XIAP downregulation in rSUM190 and rSUM149 cells using a small-molecule inhibitor (embelin), which abrogates the XIAP/procaspase-9 interaction, resulted in decreased viability, showing that XIAP is required for survival of cells with acquired resistance to GW583340. These studies establish the feasibility of development of an XIAP inhibitor that potentiates apoptosis for use in IBC patients with resistance to ErbB2-targeting agents.

Citing Articles

Exploring BIRC family genes as prognostic biomarkers and therapeutic targets in prostate cancer.

Yu X, Liu Y, Mo Z, Luo R, Chen W Discov Oncol. 2025; 16(1):240.

PMID: 40009266 PMC: 11865399. DOI: 10.1007/s12672-025-02002-7.

HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future.

Xu L, Xie Y, Gou Q, Cai R, Bao R, Huang Y Front Pharmacol. 2024; 15:1446414.

PMID: 39351085 PMC: 11439691. DOI: 10.3389/fphar.2024.1446414.

Altered ribosomal profile in acquired resistance and reversal associates with pathological response to chemotherapy in inflammatory breast cancer.

Devi G, Pai P, Lee S, Foster M, Sannareddy D, Bertucci F NPJ Breast Cancer. 2024; 10(1):65.

PMID: 39075068 PMC: 11286775. DOI: 10.1038/s41523-024-00664-0.

Prognostic value of XIAP and survivin expression in locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.

Pluta P, Jesionek-Kupnicka D, Pluta A, Brzozowski K, Braun M, Kubicka-Wolkowska J Arch Med Sci. 2023; 19(2):343-354.

PMID: 37034529 PMC: 10074301. DOI: 10.5114/aoms.2019.88509.

Adaptive stress response genes associated with breast cancer subtypes and survival outcomes reveal race-related differences.

Al Abo M, Gearhart-Serna L, Van Laere S, Freedman J, Patierno S, Hwang E NPJ Breast Cancer. 2022; 8(1):73.

PMID: 35697736 PMC: 9192737. DOI: 10.1038/s41523-022-00431-z.

References

Nikolovska-Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller P . Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem. 2004; 47(10):2430-40. DOI: 10.1021/jm030420+. View

Amantana A, London C, Iversen P, Devi G . X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther. 2004; 3(6):699-707. View

Yamagiwa Y, Marienfeld C, Meng F, Holcik M, Patel T . Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival. Cancer Res. 2004; 64(4):1293-8. DOI: 10.1158/0008-5472.can-03-2517. View

Lee H, Youn S, Kim J, Park K, Hwang C, Park W . FOXO3a turns the tumor necrosis factor receptor signaling towards apoptosis through reciprocal regulation of c-Jun N-terminal kinase and NF-kappaB. Arterioscler Thromb Vasc Biol. 2007; 28(1):112-20. DOI: 10.1161/ATVBAHA.107.153304. View

Nachmias B, Ashhab Y, Ben-Yehuda D . The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol. 2004; 14(4):231-43. DOI: 10.1016/j.semcancer.2004.04.002. View

Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L . A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A. 2006; 103(20):7795-800. PMC: 1472524. DOI: 10.1073/pnas.0602468103. View

Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B . Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res. 2004; 64(23):8558-65. DOI: 10.1158/0008-5472.CAN-04-2696. View

Geyer C, Forster J, Lindquist D, Chan S, Romieu C, Pienkowski T . Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355(26):2733-43. DOI: 10.1056/NEJMoa064320. View

Schimmer A, Dalili S, Batey R, Riedl S . Targeting XIAP for the treatment of malignancy. Cell Death Differ. 2005; 13(2):179-88. DOI: 10.1038/sj.cdd.4401826. View

10.

Medina P, Goodin S . Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008; 30(8):1426-47. DOI: 10.1016/j.clinthera.2008.08.008. View

11.

Ryan Q, Ibrahim A, Cohen M, Johnson J, Ko C, Sridhara R . FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist. 2008; 13(10):1114-9. DOI: 10.1634/theoncologist.2008-0816. View

12.

Martin A, Miller A, Emad L, Rahmani M, Walker T, Mitchell C . Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Mol Pharmacol. 2008; 74(3):807-22. PMC: 2574656. DOI: 10.1124/mol.108.047365. View

13.

Deveraux Q, Reed J . IAP family proteins--suppressors of apoptosis. Genes Dev. 1999; 13(3):239-52. DOI: 10.1101/gad.13.3.239. View

14.

Nahta R, Yu D, Hung M, Hortobagyi G, Esteva F . Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006; 3(5):269-80. DOI: 10.1038/ncponc0509. View

15.

Anderson W, Chu K, Chang S . Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?. J Clin Oncol. 2003; 21(12):2254-9. DOI: 10.1200/JCO.2003.07.082. View

16.

Van den Eynden G, Van der Auwera I, Van Laere S, Colpaert C, van Dam P, Merajver S . Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat. 2004; 85(1):13-22. DOI: 10.1023/B:BREA.0000021028.33926.a8. View

17.

Burris 3rd H, Hurwitz H, Dees E, Dowlati A, Blackwell K, ONeil B . Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005; 23(23):5305-13. DOI: 10.1200/JCO.2005.16.584. View

18.

Hunter A, LaCasse E, Korneluk R . The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis. 2007; 12(9):1543-68. DOI: 10.1007/s10495-007-0087-3. View

19.

Forozan F, Veldman R, Ammerman C, Parsa N, Kallioniemi A, Kallioniemi O . Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer. 1999; 81(8):1328-34. PMC: 2362964. DOI: 10.1038/sj.bjc.6695007. View

20.

Nguyen D, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S . Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res. 2006; 12(17):5047-54. DOI: 10.1158/1078-0432.CCR-05-2248. View